APA

Patnaik A., Gordon M., Tsai F., Papadopoulos K. P., Rasco D., Beeram M., Fu S., Janku F., Hynes S. M., Gundala S. R., Willard M. D., Zhang W., Lin A. B. & Hong D. (092018). Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. : Cancer chemotherapy and pharmacology.

Chicago

Patnaik Amita, Gordon Michael, Tsai Frank, Papadopoulos Kyriakos P, Rasco Drew, Beeram Muralidhar, Fu Siqing, Janku Filip, Hynes Scott M, Gundala Sushma R, Willard Melinda D, Zhang Wei, Lin Aimee Bence and Hong David. 092018. Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. : Cancer chemotherapy and pharmacology.

Harvard

Patnaik A., Gordon M., Tsai F., Papadopoulos K. P., Rasco D., Beeram M., Fu S., Janku F., Hynes S. M., Gundala S. R., Willard M. D., Zhang W., Lin A. B. and Hong D. (092018). Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. : Cancer chemotherapy and pharmacology.

MLA

Patnaik Amita, Gordon Michael, Tsai Frank, Papadopoulos Kyriakos P, Rasco Drew, Beeram Muralidhar, Fu Siqing, Janku Filip, Hynes Scott M, Gundala Sushma R, Willard Melinda D, Zhang Wei, Lin Aimee Bence and Hong David. Correction to: A phase I study of LY3164530, a bispecific antibody targeting MET and EGFR, in patients with advanced or metastatic cancer. : Cancer chemotherapy and pharmacology. 092018.